
ResMed (RMD) Stock Forecast & Price Target
ResMed (RMD) Analyst Ratings
Bulls say
ResMed demonstrates a robust financial outlook supported by a consistent increase in cash returns to shareholders, exemplified by a dividend increase and an aggressive share repurchase strategy. The company has experienced a significant year-over-year revenue increase, with U.S., Canada, and LATAM masks and other revenue rising by 12% in the fourth quarter of fiscal 2025, outperforming expectations by 2%. Additionally, the strategic focus on digital health initiatives positions ResMed to drive long-term growth and sustainability amid an expanding market driven by rising sleep apnea diagnoses and demographic trends.
Bears say
ResMed faces a negative outlook primarily due to concerns regarding the potential impact of GLP-1 drug uptake on the growth of its mask and device segments, which may disrupt future revenues from positive airway pressure (PAP) volumes. Despite the company currently outgrowing the market, the findings from a comprehensive survey of sleep specialists suggest that these disruptions could significantly affect sales in the medium term. This indicates that while ResMed operates in a structurally growing market due to an increase in sleep apnea diagnoses and related trends, external factors may hinder its financial performance moving forward.
This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.
ResMed (RMD) Analyst Forecast & Price Prediction
Start investing in ResMed (RMD)
Order type
Buy in
Order amount
Est. shares
0 shares